Individuals with suspected fibrotic NASH treated with FXR agonist vonafexor showed a mean 80 ms absolute reduction in cT1 at week 12 from baseline, indicating a significant reduction in liver disease activity post-treatment. These findings suggest that vonafexor is a promising therapeutic for reversing liver fibro-inflammation in NASH.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?